Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT00180895
Phase
PHASE2
Status
Terminated

Conditions

  • Burkitt Lymphoma

Eligibility Criteria

Sex
ALL
Age
6 Months - 20 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3 acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL

Key Dates

Start date
Jun 30, 2004
Status verified
Sep 2006

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Rate of patients achieving at least objective response after 2 courses of rituximab

Related Studies